Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 28, 2023
Novel Exploratory Study to Test combination of Botensilimab and Balstilimab Immunotherapy in Patients with Resectable Colorectal Cancer (NEST-1)
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 30, 2023
A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 30, 2023
Phase I Trial of Tazemetostat in Combination with Venetoclax in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 30, 2023
Liver Cirrhosis Network Cohort Study
Study Status:
Open to Enrollment
Primary Investigator:
Date: March 30, 2023
Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients with Cortisol-Secreting Adrenal Adenomas or (GRADIENT): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Relacorilant
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 4, 2023
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 6, 2023
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 6, 2023
Open Label Phase II Trial of Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) and Known Amplifications or Activating Mutations in Gene Targets of Cabozantinib Who Have Received Prior Anti-Androgen Therapy
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 6, 2023
Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 6, 2023